News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarantus BioSciences, Inc. Announces Private Placement of Convertible Debentures and Warrants


9/4/2013 9:53:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SUNNYVALE, Calif., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has entered into definitive agreements with institutional investors to raise approximately $1.4 million in a private placement of convertible debentures and warrants led by Dominion Capital. In the event the warrants are exercised in full, total proceeds to the Company resulting from this transaction will exceed $3.5 million. The funds raised will be used to fund the further development of its product development programs, MANF and LymPro. The closing of the transaction is subject to the satisfaction of customary closing conditions and is expected to occur on or before September 6, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES